Archive for category: Publications

The Biosimilar Patent Dance: When in Doubt, List It

In Amgen v. Hospira, issued August 10, the Federal Circuit provided its latest take on the “patent dance” under the Biologics Price Competition and Innovation Act (“BPCIA”).  The Federal Circuit sets a low bar for what constitutes “a claim of patent infringement could reasonably be asserted” under BPCIA and allows a reference product sponsor to potentially identify a lot more patents at the beginning of the dance than what it can reasonably assert at the end of the dance, after receiving additional information from the biosimilar applicant.  Read Limin Zheng’s article published in Daily Journal here.

Opinion: 1,166 Pieces Of Evidence And No Due Process

December 15, 2016

Focus on alleged Russian state-sponsored doping in international athletic competitions has distracted attention from the problems of the organization that is supposed to detect doping.  The focus on Russia has also distracted attention from mass bans of athletes without regard to guilt. Read Ron Katz’s article published in Law360  here.